Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Theorem Adds RadMD to its Roster of Strategic Alliances

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
Expands imaging capabilities.

Theorem Clinical Research has announced the addition of RadMD, a cutting-edge medical imaging expertise company, to its roster of strategic alliances.

“These kinds of alliances allow us to extend our capabilities to offer a greater depth and spectrum of services to our clients,” said D. Lee Spurgin Jr., Ph.D., Theorem senior vice president and general manager of medical device and diagnostic development.

Spurgin continued, “When we work with partners that we already know and trust, we feel our clients get a better end result.”

With the increasing utilization of imaging in clinical research, there has been a greater demand for expertise on the use of medical imaging in clinical trials.

RadMD offers unique services centered solely on the use of imaging in trials. They provide a consultative approach to implementing medical imaging endpoints based on extensive experience in the pharmaceutical development of both diagnostic and therapeutic drugs.

RadMD’s services include expertise in constructing customized medical imaging solutions, a unique worldwide network of more than 600 physicians and medical imaging experts available for independent image evaluations or “blinded reads”, regulatory strategy, imaging endpoint justification and extensive imaging training capabilities.

“We are excited to be able to bring our imaging expertise in clinical development to Theorem’s clientele, and look forward to working together to develop innovative products for our mutual customers and patients,” said Doug Stefanelli RadMD COO and executive vice president.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Theorem Clinical Research Expands Leadership and Prepares for Growth
Addition of Kathryn Bohannon as vice president of biopharmaceutical development and Angela Weston as vice president business development.
Thursday, November 13, 2014
Theorem Clinical Research, Charles River Form Strategic Alliance
New alliance provides nonclinical testing programs.
Monday, September 23, 2013
Ximedica Joins Theorem Clinical Research Strategic Alliance Group
Will work to design medical solutions that meet a range of safety requirements.
Thursday, September 12, 2013
Theorem Clinical Research Distributes Clinical Trial Advice
Company releases booklets to provide ICH GCP guidance for in vitro and investigational product trials.
Thursday, February 28, 2013
Theorem and Gallus Announce an Exclusive Partnership
Partnership to help companies accelerate their research, development and manufacturing of biopharmaceuticals.
Monday, August 13, 2012
Theorem Clinical Research Appoints Vice President of Global Regulatory Affairs
The CRO has announced the appointment of food and drug law expert Brian Bollwage, J.D., as Vice President of Global Regulatory Affairs.
Wednesday, January 18, 2012
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!